| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group | 
| kapsaicin 179 mg/timme, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Buprenorphine 20 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Buprenorphine 10 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| buprenorfin 5 mikrogram per timme, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| nikotin 11 mg/24 timmar, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| nikotin 22 mg/dygn, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Glyceryl trinitrate 800 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely glyceryl trinitrate 200 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely glyceryl trinitrate 400 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely glyceryl trinitrate 600 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,025 mg/dag, plåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,375 mg/dag, plåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,05 mg/dag, plåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,075 mg/dag, plåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,1 mg/dag, plåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| skopolamin 0,5 mg/24 timmar, plåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely glyceryl trinitrate 300 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,05 mg + noretindronacetat 0,14 mg/dag, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,05 mg + noretindronacetat 0,25 mg/dag, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 14 mikrogram/dag, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| etinylestradiol 0,02 mg + norelgestromin 0,15 mg per dygn, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Fentanyl 12 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| selegilin 6 mg/24 timmar, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| selegilin 9 mg/24 timmar, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| selegilin 12 mg/24 timmar, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| rivastigmin 4,6 mg/24 timmar, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| rivastigmin 9,5 mg/24 timmar, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 0,06 mg/dag, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 2.083 microgram/hour and norethisterone acetate 10.417 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 3.125 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 1.042 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 1.563 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely estradiol 1.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Rotigotine 83.333 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely estradiol 2.083 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 2.083 microgram/hour and norethindrone acetate 7.083 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely estradiol 3.333 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely estradiol 4.167 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Hyoscine 13.889 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely fentanyl 25 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Testosterone 104.167 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Buprenorphine 35 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely fentanyl 50 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely buprenorphine 52.5 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely buprenorphine 70 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely fentanyl 75 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely fentanyl 100 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely granisetron 129.167 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Rotigotine 166.667 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Glyceryl trinitrate 208.333 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Testosterone 208.333 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely testosterone 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Nicotine 291.667 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely nicotine 312.5 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely glyceryl trinitrate 416.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Nicotine 583.333 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Glyceryl trinitrate 625 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Nicotine 625 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely nicotine 875 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely nicotine 937.5 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely estradiol 2.08 microgram/1 hour and norethisterone acetate 10.4 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 1.04 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 1.56 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 1.88 microgram/hour and levonorgestrel 625 nanogram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 2.5 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely estradiol 2.08 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Ethinylestradiol 1.46 microgram/hour and norelgestromin 6.25 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 3.13 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| estradiol 4,17 mikrogram/timme, depåplåster | Has manufactured dose form | False | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely selegiline 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 2.08 microgram/hour and norethisterone acetate 5.83 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Estradiol 583 nanogram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Selegiline 500 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely oxybutynin 162 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Selegiline 375 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely nicotine 917 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Nicotine 458 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Rivastigmine 192 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Rivastigmine 396 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Rotigotine 125 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Rotigotine 41.667 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Buprenorphine 5 microgram/hour prolonged-release transdermal patch | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely nicotine 1.563 milligram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  | 
| Product containing precisely buprenorphine 15 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | True | Prolonged-release transdermal patch (dose form) | Inferred relationship | Some |  |